InSite Vision Starts Patient Enrollment in Confirmatory Phase 3 Clinical Trial of BromSite
Enrollment has begun in the confirmatory phase 3
clinical trial of BromSite (ISV-303; InSite Vision Inc.) for
the reduction of inflammation and pain after cataract
surgery.
ISV-303 combines a low dose (0.075%) of the nonsteroidal
antiinflammatory drug bromfenac with
InSite’s DuraSite drug delivery technology. This...